These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31575654)

  • 1. Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations.
    Park PH; Yamamoto TM; Li H; Alcivar AL; Xia B; Wang Y; Bernhardy AJ; Turner KM; Kossenkov AV; Watson ZL; Behbakht K; Casadei S; Swisher EM; Mischel PS; Johnson N; Bitler BG
    Mol Cancer Ther; 2020 Feb; 19(2):602-613. PubMed ID: 31575654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
    Simmons AD; Nguyen M; Pintus E
    BMC Cancer; 2020 Mar; 20(1):215. PubMed ID: 32171277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
    Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N
    Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 6. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
    Johnson N; Johnson SF; Yao W; Li YC; Choi YE; Bernhardy AJ; Wang Y; Capelletti M; Sarosiek KA; Moreau LA; Chowdhury D; Wickramanayake A; Harrell MI; Liu JF; D'Andrea AD; Miron A; Swisher EM; Shapiro GI
    Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17041-6. PubMed ID: 24085845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report.
    McFarland TR; Tandar CE; Agarwal N; Swami U
    Cancer Treat Res Commun; 2021; 29():100480. PubMed ID: 34700141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of
    Quigley D; Alumkal JJ; Wyatt AW; Kothari V; Foye A; Lloyd P; Aggarwal R; Kim W; Lu E; Schwartzman J; Beja K; Annala M; Das R; Diolaiti M; Pritchard C; Thomas G; Tomlins S; Knudsen K; Lord CJ; Ryan C; Youngren J; Beer TM; Ashworth A; Small EJ; Feng FY
    Cancer Discov; 2017 Sep; 7(9):999-1005. PubMed ID: 28450426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib-Resistant
    Biegała Ł; Gajek A; Marczak A; Rogalska A
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Lin KK; Harrell MI; Oza AM; Oaknin A; Ray-Coquard I; Tinker AV; Helman E; Radke MR; Say C; Vo LT; Mann E; Isaacson JD; Maloney L; O'Malley DM; Chambers SK; Kaufmann SH; Scott CL; Konecny GE; Coleman RL; Sun JX; Giordano H; Brenton JD; Harding TC; McNeish IA; Swisher EM
    Cancer Discov; 2019 Feb; 9(2):210-219. PubMed ID: 30425037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
    McCann KE
    Future Oncol; 2019 May; 15(15):1707-1715. PubMed ID: 30912451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling Therapy Resistance in
    Dréan A; Williamson CT; Brough R; Brandsma I; Menon M; Konde A; Garcia-Murillas I; Pemberton HN; Frankum J; Rafiq R; Badham N; Campbell J; Gulati A; Turner NC; Pettitt SJ; Ashworth A; Lord CJ
    Mol Cancer Ther; 2017 Sep; 16(9):2022-2034. PubMed ID: 28619759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
    Sakai W; Swisher EM; Karlan BY; Agarwal MK; Higgins J; Friedman C; Villegas E; Jacquemont C; Farrugia DJ; Couch FJ; Urban N; Taniguchi T
    Nature; 2008 Feb; 451(7182):1116-20. PubMed ID: 18264087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to therapy caused by intragenic deletion in BRCA2.
    Edwards SL; Brough R; Lord CJ; Natrajan R; Vatcheva R; Levine DA; Boyd J; Reis-Filho JS; Ashworth A
    Nature; 2008 Feb; 451(7182):1111-5. PubMed ID: 18264088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    Cook SA; Tinker AV
    BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
    Nesic K; Krais JJ; Wang Y; Vandenberg CJ; Patel P; Cai KQ; Kwan T; Lieschke E; Ho GY; Barker HE; Bedo J; Casadei S; Farrell A; Radke M; Shield-Artin K; Penington JS; Geissler F; Kyran E; Betsch R; Xu L; Zhang F; Dobrovic A; Olesen I; Kristeleit R; Oza A; McNeish I; Ratnayake G; Traficante N; ; DeFazio A; Bowtell DDL; Harding TC; Lin K; Swisher EM; Kondrashova O; Scott CL; Johnson N; Wakefield MJ
    Mol Cancer; 2024 Aug; 23(1):158. PubMed ID: 39103848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.